| content | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Odanacatib
|
|
| Systematic (IUPAC) name | |
| (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl- 2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)- [1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C25H27F4N3O3S |
| Mol. mass | 525.56 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis. It is an inhibitor of cathepsin K,1 an enzyme involved in bone resorption.
It is being developed by Merck & Co. As of May 2008, Merck is conducting phase III clinical trials.
References
- ^ Gauthier JY, Chauret N, Cromlish W, et al (February 2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg. Med. Chem. Lett. 18 (3): 923–8. doi:. PMID 18226527.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
